Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality
Over the past 18 months, the growing team at Repare Therapeutics has been quietly setting up shop in Versant Ventures’ discovery ops and focusing on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
